Topical glaucoma medications - Clinical implications for the ocular surface.

Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.

• Publication year

  2022

• Venue

  The ocular surface

• Publication date

  2022-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jtos.2022.07.007PMID 35921942
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug induced cicatrizing conjunctivitis: A case series with review of etiopathogenesis, diagnosis and management.

  2022cited by this paper
• Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease

  2022cited by this paper
• RETRACTED ARTICLE: Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study

  2021cited by this paper
• Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia

  2021cited by this paper
• Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial

  2021cited by this paper
• Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops.

  2021cited by this paper
• Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost

  2021cited by this paper
• The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients

  2021cited by this paper
• Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma

  2021cited by this paper
• Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study

  2021cited by this paper
• Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film

  2021cited by this paper
• Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma

  2021cited by this paper
• The effects of ocular surface disease on optical coherence tomography test results in patients with glaucoma

  2021cited by this paper
• Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension

  2021cited by this paper
• The Effect of Long-Term Usage of Single-Agent Antiglaucomatous Drops with Different Preservatives on Cornea Biomechanics

  2021cited by this paper
• Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study

  2021cited by this paper
• Comparative analysis of ocular redness score evaluated automatically in glaucoma patients under different topical medications

  2020cited by this paper
• Change of tear lipid mediators in a post-trabeculectomy cohort.

  2020cited by this paper
• Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure.

  2020cited by this paper
• Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film

  2020cited by this paper
• Profiling ocular surface responses to preserved and non‐preserved topical glaucoma medications: A 2‐year randomized evaluation study

  2020cited by this paper
• Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface

  2020cited by this paper
• Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

  2020cited by this paper
• Impact of Ocular Surface Disease Treatment in Patients with Glaucoma

  2020cited by this paper
• Evaluation of ocular surface disease in elderly patients with glaucoma: expression of matrix metalloproteinase-9 in tears

  2020cited by this paper
• Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients

  2020cited by this paper
• Preliminary Outcomes of Temporary Collagen Punctal Plugs for Patients with Dry Eye and Glaucoma

  2020cited by this paper
• Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana.

  2020cited by this paper
• Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination

  2020cited by this paper
• Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma

  2020cited by this paper
• Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages

  2020cited by this paper
• Effects of topical antiglaucomatous medications on central corneal epithelial thickness by anterior segment optical coherence tomography

  2020cited by this paper
• Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue

  2019cited by this paper
• Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study

  2019cited by this paper
• Evaluation of Antiglaucomatous Drops on Conjunctival Thickness in Patients with Primary Open-Angle Glaucoma

  2019influential reference
• The effect of topical latanoprost on corneal clarity; 1-year prospective study†

  2019cited by this paper
• Ocular Surface Disease and Glaucoma Medications: A Clinical Approach

  2019cited by this paper
• Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives

  2019cited by this paper
• Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film

  2019cited by this paper
• Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs

  2019cited by this paper
• Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension.

  2019cited by this paper
• Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma

  2019cited by this paper
• Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life

  2019cited by this paper
• Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease.

  2019cited by this paper
• Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series

  2019cited by this paper
• Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma

  2019cited by this paper
• Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial

  2018cited by this paper
• Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients

  2018cited by this paper
• The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review

  2018influential reference
• Anterior-Segment Optical Coherence Tomography and Scanning Electron Microscopy to Evaluate Corneal Epithelial Changes in Patients Undergoing Glaucoma Therapy

  2018cited by this paper
• Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

  2018influential reference
• Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride

  2018cited by this paper
• Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases

  2018cited by this paper
• Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive Therapy

  2018cited by this paper
• Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues

  2018cited by this paper
• Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension

  2018cited by this paper
• Effect of long-term topical latanoprost medication on conjunctival thickness in patients with glaucoma.

  2018influential reference
• Ocular Redness Measured with the Keratograph 5M in Patients Using Anti-Glaucoma Eye Drops

  2018cited by this paper
• High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand

  2018cited by this paper
• Structural and molecular tear film changes in glaucoma.

  2018cited by this paper
• Meibomian Gland Features and Conjunctival Goblet Cell Density in Glaucomatous Patients Controlled With Prostaglandin/Timolol Fixed Combinations: A Case Control, Cross-sectional Study

  2018cited by this paper
• The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension

  2018cited by this paper
• Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness

  2018cited by this paper
• Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

  2018cited by this paper
• Tear biomarkers in latanoprost and bimatoprost treated eyes

  2018cited by this paper
• Cytokine expression in tears of patients with glaucoma or dry eye disease: A prospective, observational cohort study

  2018cited by this paper
• Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.

  2018cited by this paper
• Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye.

  2018cited by this paper
• TFOS DEWS II Definition and Classification Report.

  2017cited by this paper
• Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost.

  2017cited by this paper
• Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study

  2017cited by this paper
• Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy.

  2017cited by this paper
• The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells

  2017cited by this paper
• TFOS DEWS II Tear Film Report.

  2017cited by this paper
• Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications

  2017cited by this paper
• The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface

  2017cited by this paper
• Ocular Surface Disease in Patients under Topical Treatment for Glaucoma

  2017cited by this paper
• Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study

  2017cited by this paper
• TFOS DEWS II Management and Therapy Report.

  2017cited by this paper
• [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].

  2016cited by this paper
• 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy

  2016cited by this paper
• Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost

  2016cited by this paper
• Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma

  2016cited by this paper
• Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans

  2016cited by this paper
• The Ocular Surface in Medically Controlled Glaucoma: An In Vivo Confocal Study.

  2016cited by this paper
• Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial

  2016cited by this paper
• Vitamin A Palmitate and Carbomer Gel Protects the Conjunctiva of Patients With Long-term Prostaglandin Analogs Application

  2016cited by this paper
• Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome

  2016cited by this paper
• Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment

  2016cited by this paper
• Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension

  2016cited by this paper
• The Impact of Glaucoma Medications on Corneal Wound Healing

  2016cited by this paper
• Tear Lipid Layer Thickness Change and Topical Anti-Glaucoma Medication Use

  2016cited by this paper
• Dry eye specific quality of life in veterans using glaucoma drops.

  2015cited by this paper
• The Utility of an Artificial Substitute to Improve Corneal Sensitivity in Glaucomatous Patients on Chronic Therapy with Prostaglandin Analogs

  2015cited by this paper
• Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications

  2015cited by this paper
• Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma Treatments

  2015cited by this paper
• Conjunctival matrix metalloproteinases and their inhibitors in glaucoma patients

  2015cited by this paper
• Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma

  2015cited by this paper
• Prostaglandin agonist effect on matrix metalloproteinase aqueous levels in glaucoma patients.

  2015cited by this paper
• Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface

  2015cited by this paper

• Impact of mono- or multitherapy on ocular surface health and quality of life after 5 years of follow-up in the Glaucoma Intensive Treatment Study (GITS).

  2026cites this paper
• Analysis of risk factors associated with meibomian gland orifice obstruction severity in glaucoma patients: a clinical investigation

  2025cites this paper
• Increased near add power in pre-presbyopic glaucoma patients treated with medication.

  2025cites this paper
• Retinoprotective Effects of Abscisic Acid in Ischemic Retinopathy Mouse Model

  2025cites this paper
• Unraveling the effects of serial intravitreal Aflibercept injections on the ocular surface of patients with glaucoma and retinal comorbidity

  2025cites this paper
• Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost

  2025cites this paper
• Characteristics of tear meniscus, punctum, and cornea epithelium using an anterior segment optical coherence tomography in glaucoma

  2025cites this paper
• A Deep Learning Model for Detecting the Eyes Receiving Glaucoma Medications Using Anterior Segment Images

  2025cites this paper
• One-year outcome of intense pulsed light therapy for refractory meibomian gland dysfunction in patients continuously exposed to topical glaucoma medications: a comparative study

  2025cites this paper
• Clinical Factors Predicting Favorable Response to Intense Pulsed Light Therapy for Refractory Meibomian Gland Dysfunction: A 6-Month Cohort Study.

  2025cites this paper
• Which factor have more adverse effect on ocular surface of patients treated with antiglaucoma drops; drug type, number of drugs or drug intensity?

  2025cites this paper
• TFOS DEWS III Digest Report.

  2025cites this paper
• Nanotherapeutics for ocular posterior segment diseases therapy: Towards its advances and challenges

  2025cites this paper
• Alpinetin Nanoparticles Alleviate Optic Nerve Injury Induced by Acute Glaucoma via LRP1‐PPARγ Mediated Regulation of Microglial Lipid Metabolism

  2025cites this paper
• TFOS DEWS III.

  2025cites this paper
• Real-Life Study on the Efficacy and Tolerance of a Preservative-Free Surfactant-Free Latanoprost Eye Drop in Patients with Glaucoma

  2024influential citation
• Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024%

  2024cites this paper
• Novel treatments for dry eye syndrome.

  2024cites this paper
• Glaucoma and ocular surface

  2024cites this paper
• Dry Eye Disease Symptoms Among Glaucoma Patients at a Portuguese Hospital

  2024cites this paper
• Topical glaucoma medications − Possible implications on the meibomian glands

  2024cites this paper
• Topical anti-glaucoma medications effects on meibomian glands: systematic review and meta-analysis.

  2024cites this paper
• A Comparative Study of Ocular Surface Disease in Childhood Glaucoma

  2024cites this paper
• Near Add Power of Glaucoma Patients with Early Presbyopia

  2024cites this paper
• Association between the use of prostaglandin analogues and ocular surface disease: a systematic review

  2024cites this paper
• Comparison of postoperative cyclosporine 2.0% versus betamethasone 0.1% eye drops following trabeculectomy: A randomized clinical trial

  2024cites this paper
• Changes of the Types and Daily Costs of Topical Antiglaucoma Medications from 2006 to 2021 in China

  2023cites this paper
• Neurotrophic keratopathy: Clinical presentation and outcomes in 354 eyes in a community-based population

  2023cites this paper
• Evaluation of ocular surface following PreserFlo Microshunt implantation: Functional outcomes and quality of life

  2023cites this paper
• Prevalence of dry eye disease in the low vision population at the University of Colorado

  2023cites this paper
• Clinical and Optical Coherence Tomography Evidence of Aqueous Humor Flow from the Suprachoroidal Space to Conjunctival Lymphatics

  2023cites this paper
• Pharmacokinetic and Ocular Toxicity Evaluation of Latanoprost Ophthalmic Solution, 0.005%, with Preservative Level Reduced to Below the Limit of Quantitation

  2023cites this paper
• Chronic Open Angle Glaucoma: a Biopsychosocial Approach to Patient Care.

  2023cites this paper
• Case report: Medical treatment for limbal epithelial stem cell deficiency in patients treated for glaucoma

  2023cites this paper
• Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment.

  2023cites this paper
• Use Pattern of Ophthalmic Antiglaucoma Agents with and without Preservatives: A Cross-Sectional Study

  2023cites this paper
• A comparison between hyaluronic acid and other single ingredient eye drops for dry eye, a review

  2023cites this paper
• Is fat the future for saving sight? Bioactive lipids and their impact on glaucoma.

  2023cites this paper
• Influence of BAKs on Tear Film Lipid Layer: in vitro and in silico models.

  2023cites this paper